Evidence map›Paper›PMID 25299963›Full record

ReviewAtherosclerosis2014

The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective.

Naomi J Rankin, David Preiss, Paul Welsh, Karl E V Burgess, Scott M Nelson, Debbie A Lawlor, Naveed Sattar

Full text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Atherosclerosis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Searching for Metabolic Markers of Stroke in Human Plasma via NMR Analysis.International journal of molecular sciences · 2023
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Plasma metabolite biomarkers predictive of radiation induced cardiotoxicity.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2020
    Article
  17. Review
  18. Immunomodulatory Protein fromInternational journal of molecular sciences · 2019
    Article
  19. High-Throughput Metabolomics by 1D NMR.Angewandte Chemie (International ed. in English) · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Naomi J RankinBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK; Glasgow Polyomics, Joseph Black Building, University of Glasgow, Glasgow, G12 8QQ, UK. Electronic address: Naomi.Rankin@glasgow.ac.uk.
David PreissBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK.
Paul WelshBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK.
Karl E V BurgessGlasgow Polyomics, Joseph Black Building, University of Glasgow, Glasgow, G12 8QQ, UK.
Scott M NelsonSchool of Medicine, University of Glasgow, Glasgow, G12 8TA, UK.
Debbie A LawlorMRC Integrative Epidemiology Unit at the University of Bristol, Bristol, BS8 2BN, UK; School of Social and Community Medicine, University of Bristol, Bristol, BS8 2PS, UK.
Naveed SattarBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK. Electronic address: Naveed.Sattar@glasgow.ac.uk.

Funding

British Heart Foundation FS/12/62/29889Medical Research Council MC_UU_12013/5Wellcome TrustWellcome Trust WT097821MF
6 · The paper itself

Abstract

The ability to phenotype metabolic profiles in serum has increased substantially in recent years with the advent of metabolomics. Metabolomics is the study of the metabolome, defined as those molecules with an atomic mass less than 1.5 kDa. There are two main metabolomics methods: mass spectrometry (MS) and proton nuclear magnetic resonance ((1)H NMR) spectroscopy, each with its respective benefits and limitations. MS has greater sensitivity and so can detect many more metabolites. However, its cost (especially when heavy labelled internal standards are required for absolute quantitation) and quality control is sub-optimal for large cohorts. (1)H NMR is less sensitive but sample preparation is generally faster and analysis times shorter, resulting in markedly lower analysis costs. (1)H NMR is robust, reproducible and can provide absolute quantitation of many metabolites. Of particular relevance to cardio-metabolic disease is the ability of (1)H NMR to provide detailed quantitative data on amino acids, fatty acids and other metabolites as well as lipoprotein subparticle concentrations and size. Early epidemiological studies suggest promise, however, this is an emerging field and more data is required before we can determine the clinical utility of these measures to improve disease prediction and treatment. This review describes the theoretical basis of (1)H NMR; compares MS and (1)H NMR and provides a tabular overview of recent (1)H NMR-based research findings in the atherosclerosis field, describing the design and scope of studies conducted to date. (1)H NMR metabolomics-CVD related research is emerging, however further large, robustly conducted prospective, genetic and intervention studies are needed to advance research on CVD risk prediction and to identify causal pathways amenable to intervention.

Indexed as

BiomarkersCardiovascular DiseasesCardiovascular SystemExerciseHumansLipoproteinsMagnetic Resonance SpectroscopyMass SpectrometryMetabolomicsMetforminReproducibility of ResultsBiomarkersLipoproteinsMetforminAdvanced lipoprotein testing (ALP)BiomarkersCardiovascular disease (CVD)LipoproteinMass spectrometry (MS)MetabolomicsNuclear magnetic resonance ((1)H NMR)

Identifiers

PMID25299963
PMCPMC4232363

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.